<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">36216081</PMID><DateCompleted><Year>2023</Year><Month>02</Month><Day>07</Day></DateCompleted><DateRevised><Year>2023</Year><Month>04</Month><Day>02</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1097-6825</ISSN><JournalIssue CitedMedium="Internet"><Volume>151</Volume><Issue>2</Issue><PubDate><Year>2023</Year><Month>Feb</Month></PubDate></JournalIssue><Title>The Journal of allergy and clinical immunology</Title><ISOAbbreviation>J Allergy Clin Immunol</ISOAbbreviation></Journal><ArticleTitle>Airway-delivered short-chain fatty acid acetate boosts antiviral immunity during rhinovirus infection.</ArticleTitle><Pagination><StartPage>447</StartPage><EndPage>457.e5</EndPage><MedlinePgn>447-457.e5</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.jaci.2022.09.026</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0091-6749(22)01331-8</ELocationID><Abstract><AbstractText Label="BACKGROUND">Microbiota are recognized to play a major role in regulation of immunity through release of immunomodulatory metabolites such as short-chain fatty acids (SCFAs). Rhinoviruses (RVs) induce upper respiratory tract illnesses and precipitate exacerbations of asthma and chronic obstructive pulmonary disease through poorly understood mechanisms. Local interactions between SCFAs and antiviral immune responses in the respiratory tract have not been previously investigated.</AbstractText><AbstractText Label="OBJECTIVE">We sought to investigate whether pulmonary metabolite manipulation through lung-delivered administration of SCFAs can modulate antiviral immunity to RV infection.</AbstractText><AbstractText Label="METHODS">We studied the effects of intranasal administration of the SCFAs acetate, butyrate, and propionate on basal expression of antiviral signatures, and of acetate in a mouse model of RV infection and in RV-infected lung epithelial cell lines. We additionally assessed the effects of acetate, butyrate, and propionate on RV infection in differentiated human primary bronchial epithelial cells.</AbstractText><AbstractText Label="RESULTS">Intranasal acetate administration induced basal upregulation of IFN-β, an effect not observed with other SCFAs. Butyrate induced RIG-I expression. Intranasal acetate treatment of mice increased interferon-stimulated gene and IFN-λ expression during RV infection and reduced lung virus loads at 8 hours postinfection. Acetate ameliorated virus-induced proinflammatory responses with attenuated pulmonary mucin and IL-6 expression observed at day 4 and 6 postinfection. This interferon-enhancing effect of acetate was confirmed in human bronchial and alveolar epithelial cell lines. In differentiated primary bronchial epithelial cells, butyrate treatment better modulated IFN-β and IFN-λ gene expression during RV infection.</AbstractText><AbstractText Label="CONCLUSIONS">SCFAs augment antiviral immunity and reduce virus load and proinflammatory responses during RV infection.</AbstractText><CopyrightInformation>Copyright © 2022 The Authors. Published by Elsevier Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Antunes</LastName><ForeName>Krist Helen</ForeName><Initials>KH</Initials><AffiliationInfo><Affiliation>Laboratory of Clinical and Experimental Immunology - Pontifical Catholic University of Rio Grande do Sul, Porto Alegre; National Heart and Lung Institute and, Department of Infectious Disease, Imperial College London, London.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Singanayagam</LastName><ForeName>Aran</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Centre for Molecular Bacteriology and Infection, Department of Infectious Disease, Imperial College London, London.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Williams</LastName><ForeName>Lily</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>School of Biomedical Sciences and Pharmacy, The University of Newcastle, Newcastle.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Faiez</LastName><ForeName>Tasnim Syakirah</ForeName><Initials>TS</Initials><AffiliationInfo><Affiliation>Centre for Molecular Bacteriology and Infection, Department of Infectious Disease, Imperial College London, London.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Farias</LastName><ForeName>Ana</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>National Heart and Lung Institute and, Department of Infectious Disease, Imperial College London, London.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jackson</LastName><ForeName>Millie M</ForeName><Initials>MM</Initials><AffiliationInfo><Affiliation>Centre for Molecular Bacteriology and Infection, Department of Infectious Disease, Imperial College London, London.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Faizi</LastName><ForeName>Fatima K</ForeName><Initials>FK</Initials><AffiliationInfo><Affiliation>Centre for Molecular Bacteriology and Infection, Department of Infectious Disease, Imperial College London, London.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Aniscenko</LastName><ForeName>Julia</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>National Heart and Lung Institute and, Department of Infectious Disease, Imperial College London, London.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kebadze</LastName><ForeName>Tatiana</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>National Heart and Lung Institute and, Department of Infectious Disease, Imperial College London, London.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chander Veerati</LastName><ForeName>Punnam</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>School of Biomedical Sciences and Pharmacy, The University of Newcastle, Newcastle.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wood</LastName><ForeName>Lisa</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>School of Biomedical Sciences and Pharmacy, The University of Newcastle, Newcastle.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bartlett</LastName><ForeName>Nathan W</ForeName><Initials>NW</Initials><AffiliationInfo><Affiliation>National Heart and Lung Institute and, Department of Infectious Disease, Imperial College London, London; School of Biomedical Sciences and Pharmacy, The University of Newcastle, Newcastle.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Duarte de Souza</LastName><ForeName>Ana Paula</ForeName><Initials>AP</Initials><AffiliationInfo><Affiliation>Laboratory of Clinical and Experimental Immunology - Pontifical Catholic University of Rio Grande do Sul, Porto Alegre; National Heart and Lung Institute and, Department of Infectious Disease, Imperial College London, London. Electronic address: ana.duarte@pucrs.br.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Johnston</LastName><ForeName>Sebastian L</ForeName><Initials>SL</Initials><AffiliationInfo><Affiliation>National Heart and Lung Institute and, Department of Infectious Disease, Imperial College London, London; Asthma UK Centre in Allergic Mechanisms of Asthma, London. Electronic address: s.johnston@imperial.ac.uk.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>MR/V000098/1</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>10</Month><Day>07</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Allergy Clin Immunol</MedlineTA><NlmUniqueID>1275002</NlmUniqueID><ISSNLinking>0091-6749</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000998">Antiviral Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011422">Propionates</NameOfSubstance></Chemical><Chemical><RegistryNumber>9008-11-1</RegistryNumber><NameOfSubstance UI="D007372">Interferons</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000085">Acetates</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D002087">Butyrates</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000998" MajorTopicYN="N">Antiviral Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012229" MajorTopicYN="N">Rhinovirus</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011422" MajorTopicYN="N">Propionates</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010850" MajorTopicYN="Y">Picornaviridae Infections</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007372" MajorTopicYN="N">Interferons</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001980" MajorTopicYN="N">Bronchi</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004769" MajorTopicYN="Y">Enterovirus Infections</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004847" MajorTopicYN="N">Epithelial Cells</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000085" MajorTopicYN="N">Acetates</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002087" MajorTopicYN="N">Butyrates</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Human rhinovirus</Keyword><Keyword MajorTopicYN="N">acetate</Keyword><Keyword MajorTopicYN="N">antiviral response</Keyword><Keyword MajorTopicYN="N">butyrate</Keyword><Keyword MajorTopicYN="N">microbiota</Keyword><Keyword MajorTopicYN="N">short-chain fatty acids</Keyword><Keyword MajorTopicYN="N">type-I and type-III interferons</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2021</Year><Month>11</Month><Day>2</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2022</Year><Month>8</Month><Day>3</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>9</Month><Day>9</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>10</Month><Day>11</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>2</Month><Day>8</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>10</Month><Day>10</Day><Hour>19</Hour><Minute>23</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36216081</ArticleId><ArticleId IdType="doi">10.1016/j.jaci.2022.09.026</ArticleId><ArticleId IdType="pii">S0091-6749(22)01331-8</ArticleId></ArticleIdList></PubmedData></PubmedArticle>